A joint research team led by Dr. Akira Kunitomi, a former postdoctoral fellow at CiRA (currently a researcher at the Gladstone Institute of Cardiovascular Disease), and ID Pharma Co., Ltd., has established a new method for naive iPS cell generation that uses a temperature-sensitive Sendai virus vector developed by the group to remove the vectors rapidly.